SecurityTGTX / TG Therapeutics, Inc.
IndustryPharmaceutical Preparations
Institutional Buyers81
Opened Positions20

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in TGTX / TG Therapeutics, Inc. include Jefferies Group LLC, Perceptive Advisors Llc, Man Group plc, Parallax Volatility Advisers, L.P., Mycio Wealth Partners, Llc, Balyasny Asset Management Llc, Nexthera Capital Lp, HAP Trading, LLC, Hsbc Holdings Plc, Mackay Shields Llc, Jacobs Levy Equity Management, Inc, Jane Street Group, Llc, Birchview Capital, LP, Xact Kapitalforvaltning AB, Fifth Third Bancorp, Hsbc Holdings Plc, Piedmont Investment Advisors Llc, WASHINGTON TRUST Co, Advisornet Financial, Inc, and Fny Investment Advisers, Llc.

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Option Prev Shares Shares Change
(Percent)
Prev Value
(x$1000)
Current Value (x$1000) Change
(Percent)
2018‑08‑14 13F-HR BANK OF AMERICA CORP /DE/ 31,634 101,704 221.50 449 1,337 197.77
2018‑08‑10 13F-HR Quantitative Investment Management, LLC 115,600 148,100 28.11 1,641 1,947 18.65
2018‑08‑14 13F-HR Jefferies Group LLC 0 4,800 0 63
2018‑07‑25 13F-HR BNP PARIBAS ARBITRAGE, SA 10,764 11,186 3.92 152,849 147,096 -3.76
2018‑08‑09 13F-HR BlackRock Inc. 3,475,206 4,081,050 17.43 49,348 53,667 8.75
2018‑08‑14 13F-HR VANGUARD GROUP INC 2,548,704 2,789,597 9.45 36,191 36,683 1.36
2017‑01‑13 13F-HR MetLife Securities, Inc 0 4,000 0.00 0 19
2018‑08‑14 13F-HR ROYAL BANK OF CANADA 7,434 14,198 90.99 106 187 76.42
2018‑07‑26 13F-HR Advisornet Financial, Inc 300 4
2018‑08‑14 13F-HR Parallax Volatility Advisers, L.P. Call 75,000 986
2018‑08‑08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 268,174 313,752 17.00 3,809 4,126 8.32
2018‑08‑06 13F-HR STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 21,854 22,044 0.87 310 290 -6.45
2018‑08‑07 13F-HR Quantitative Systematic Strategies LLC 0 11,086 0 146
2018‑08‑14 13F-HR DEUTSCHE BANK AG\ 56,252 94,171 67.41 797 1,237 55.21
2018‑08‑14 13F-HR Man Group plc 80,250 1,055
2018‑08‑10 13F-HR HSBC HOLDINGS PLC Call 30,300 398
2018‑08‑14 13F-HR Jefferies Group LLC Call 125,900 1,656
2018‑08‑14 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 464,391 469,241 1.04 6,595 6,171 -6.43
2018‑08‑06 13F-HR MACKAY SHIELDS LLC 28,200 371
2018‑08‑14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 78,200 90,540 15.78 1,110 1,191 7.30
2018‑08‑14 13F-HR STATE STREET CORP 3,118,261 3,712,103 19.04 44,278 48,811 10.24
2018‑08‑13 13F-HR GROUP ONE TRADING, L.P. 181,477 198,049 9.13 2,577 2,604 1.05
2018‑08‑14 13F-HR Tower Research Capital LLC (TRC) 2,627 5,427 106.59 37 71 91.89
2018‑08‑14 13F-HR Invesco Ltd. 0 177,686 0 2,337
2018‑08‑06 13F-HR RHUMBLINE ADVISERS 46,152 54,587 18.28 655 718 9.62
2018‑08‑14 13F-HR Opaleye Management Inc. 274,200 625,000 127.94 3,893 8,218 111.10
2018‑08‑02 13F-HR Birchview Capital, LP 15,000 197
2018‑08‑14 13F-HR MACQUARIE GROUP LTD 52,224 67,601 29.44 742 889 19.81
2018‑08‑13 13F-HR Advisor Group, Inc. 3,765 4,365 15.94 54 57 5.56
2018‑08‑14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 122,466 124,424 1.60 1,739 1,636 -5.92
2018‑08‑14 13F-HR A.R.T. Advisors, LLC 0 78,652 0 1,034
2018‑08‑14 13F-HR NEXTHERA CAPITAL LP 0 72,200 0 949
2018‑08‑14 13F-HR MORGAN STANLEY 158,116 246,853 56.12 2,245 3,246 44.59
2018‑08‑14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 0 78 0 1
2018‑08‑14 13F-HR TWO SIGMA ADVISERS, LP 30,700 52,100 69.71 436 685 57.11
2018‑08‑10 13F-HR FEDERATED INVESTORS INC /PA/ 57,539 74,643 29.73 817 982 20.20
2018‑08‑02 13F-HR Atlantic Trust Group, LLC 600 1,800 200.00 9 24 166.67
2018‑07‑19 13F-HR MYCIO WEALTH PARTNERS, LLC 70,200 923
2018‑08‑15 13F-HR Metlife Investment Advisors, Llc 20,926 28,284 35.16 297 372 25.25
2018‑08‑10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 0 5,312 0 70
2018‑08‑14 13F-HR Candriam Luxembourg S.C.A. 360,000 425,000 18.06 5,112 5,589 9.33
2018‑08‑14 13F-HR FIFTH THIRD BANCORP 6,600 87
2018‑08‑14 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 26,710 351
2017‑02‑10 13F-HR BlackRock Fund Advisors 1,024,196 1,178,520 15.07 7,927 5,480 -30.87
2018‑08‑03 13F-HR SEI INVESTMENTS CO 44 66 50.00 1 1 0.00
2018‑07‑30 13F-HR SIMPLEX TRADING, LLC 0 57,018 0 749
2018‑08‑13 13F-HR Ameritas Investment Partners, Inc. 4,260 4,898 14.98 60 64 6.67
2018‑08‑08 13F-HR AMERICAN INTERNATIONAL GROUP INC 32,823 38,541 17.42 466 507 8.80
2018‑07‑30 13F-HR Raymond James Financial Services Advisors, Inc. 139,071 144,236 3.71 1,975 1,897 -3.95
2018‑08‑15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 16,358 19,974 22.11 232,284 262,658 13.08
2018‑08‑15 13F-HR JANE STREET GROUP, LLC Put 21,600 284
2018‑08‑14 13F-HR GOLDMAN SACHS GROUP INC 344,028 363,181 5.57 4,885 4,776 -2.23
2018‑08‑10 13F-HR HSBC HOLDINGS PLC 3,939 51
2018‑07‑11 13F-HR Xact Kapitalforvaltning AB 10,600 139
2018‑02‑09 13F-HR RidgeWorth Capital Management LLC 0 41,833 0 343
2018‑08‑14 13F-HR/A CITADEL ADVISORS LLC Call 164,100 216,500 31.93 2,330 2,847 22.19
2018‑08‑14 13F-HR BALYASNY ASSET MANAGEMENT LLC 52,060 685
2018‑08‑14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 498,251 588,930 18.20 7,075 7,744 9.46
2018‑08‑01 13F-HR WELLS FARGO & COMPANY/MN 39,535 888,768 2,148.05 562 11,686 1,979.36
2017‑02‑10 13F-HR BlackRock Institutional Trust Company, N.A. 953,952 968,608 1.54 7,384 4,504 -39.00
2018‑08‑07 13F-HR IFP Advisors, Inc 1,700 2,000 17.65 24 26 8.33
2018‑08‑14 13F-HR EMORY UNIVERSITY 0 195,463 0 2,570
2018‑08‑14 13F-HR UNITED CAPITAL FINANCIAL ADVISERS, LLC 50,000 66,000 32.00 710 868 22.25
2018‑08‑14 13F-HR/A CITADEL ADVISORS LLC 189,915 214,149 12.76 2,697 2,816 4.41
2018‑08‑10 13F-HR WASHINGTON TRUST Co 342 4
2018‑07‑18 13F-HR Fny Investment Advisers, Llc Call 10 0
2018‑07‑27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 1,027 14
2018‑08‑13 13F-HR HAP Trading, LLC Put 45,000 21
2018‑08‑10 13F-HR Artal Group S.A. 250,000 400,000 60.00 3,550 5,260 48.17
2018‑08‑14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 36,779 42,963 16.81 522 565 8.24
2018‑08‑03 13F-HR STATE OF WISCONSIN INVESTMENT BOARD 41,000 60,300 47.07 582 793 36.25
2017‑02‑10 13F-HR BlackRock Group LTD 17,779 18,955 6.61 138 87 -36.96
2018‑08‑14 13F-HR NEXTHERA CAPITAL LP Call 50,000 658
2018‑08‑15 13F-HR JANE STREET GROUP, LLC Call 40,400 60,400 49.50 574 794 38.33
2018‑08‑10 13F-HR Cutler Group LP Call 11,000 11,500 4.55 14 5 -64.29
2018‑08‑14 13F-HR RA Capital Management, LLC 2,472,344 4,278,796 73.07 35,107 56,266 60.27
2018‑08‑14 13F-HR MILLENNIUM MANAGEMENT LLC 389,990 525,552 34.76 5,538 6,911 24.79
2018‑08‑14 13F-HR PERCEPTIVE ADVISORS LLC Put 100,000 258
2018‑08‑10 13F-HR CITIGROUP INC 92,445 99,458 7.59 1,312 1,309 -0.23
2018‑09‑18 13F-HR/A NORTHERN TRUST CORP 630,301 751,725 19.26 8,951 9,885 10.43
2018‑08‑14 13F-HR TEACHERS ADVISORS INC 111,959 122,184 9.13 1,590 1,607 1.07
2018‑08‑14 13F-HR D. E. Shaw & Co., Inc. 195,524 257,574 31.74 2,776 3,387 22.01
2018‑08‑13 13F-HR ALLIANCEBERNSTEIN L.P. 59,940 62,640 4.50 851 824 -3.17
2018‑07‑26 13F-HR TCI Wealth Advisors, Inc. 0 100 0 1
2018‑08‑14 13F-HR Voya Investment Management LLC 22,521 23,571 4.66 320 310 -3.12
2018‑08‑14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 446,600 568,600 27.32 6,342 7,477 17.90
TGTX : TG Therapeutics Stock Analysis and Research Report

2017-11-09 - Asif

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Related News Stories

Your Daily Pharma Scoop: TGTX Positive Data In MS, Iovance Trial Delay

2018-10-12 seekingalpha
After its initial hiccup earlier with its CLL drug, this news should bolster the stock a little. (7-0)

Major Biopharma Catalysts to Watch For in October

2018-10-06 247wallst
Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-7)

Major Biopharma Catalysts on October’s FDA Calendar

2018-09-29 247wallst
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which can spell disaster for a stock, comes great reward as well. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-18)

Tyme Technologies (TYME) Shares March Higher, Can It Continue?

2018-09-28 zacks
As of late, it has definitely been a great time to be an investor in Tyme Technologies, Inc. (TYME - Free Report) . The stock has moved higher by 22.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. (16-0)

Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?

2018-09-28 zacks
Ra Pharmaceuticals, Inc. (RARX - Free Report) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue? (16-0)

CUSIP: 88322Q108